130 related articles for article (PubMed ID: 37845152)
1. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors.
Lombardi R; Mantovani A; Cespiati A; Francione P; Maffi G; Del Zanna E; Maffeis C; Colecchia A; Passigato N; Ferrarese A; Cusumanu CD; Villani R; Orsi E; Grancini V; Airaghi L; Bignamini D; Serviddio G; Targher G; Dongiovanni P; Fargion S; Fracanzani AL
Dig Liver Dis; 2024 Apr; 56(4):551-558. PubMed ID: 37845152
[TBL] [Abstract][Full Text] [Related]
2. Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists.
Gracen L; Muthukumara W; Aikebuse M; Russell A; O'Beirne J; Irvine KM; Williams S; Puri G; Valery PC; Hayward KL; Powell EE
Ann Hepatol; 2023; 28(6):101142. PubMed ID: 37468097
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Adverse Effect of Liver Stiffness on Glycaemic Control in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study.
Mantovani A; Taverna A; Cappelli D; Beatrice G; Csermely A; Sani E; Byrne CD; Targher G
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293337
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus and moderate to severe hepatic fibrosis: A retrospective study.
Tyagi K; Madan S; Prakash Bhatt S; Ansari IA; Dutta K; Misra A
Clin Nutr ESPEN; 2023 Oct; 57():305-310. PubMed ID: 37739673
[TBL] [Abstract][Full Text] [Related]
5. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials.
Jin Z; Yuan Y; Zheng C; Liu S; Weng H
J Diabetes Complications; 2023 Aug; 37(8):108558. PubMed ID: 37499274
[TBL] [Abstract][Full Text] [Related]
6. Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study.
Mantovani A; Zusi C; Csermely A; Salvagno GL; Colecchia A; Lippi G; Maffeis C; Targher G
Hormones (Athens); 2022 Sep; 21(3):477-486. PubMed ID: 35831700
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
Cardoso CRL; Villela-Nogueira CA; Leite NC; Salles GF
Cardiovasc Diabetol; 2021 Sep; 20(1):193. PubMed ID: 34560854
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review.
Dwinata M; Putera DD; Hasan I; Raharjo M
Clin Exp Hepatol; 2020 Dec; 6(4):339-346. PubMed ID: 33511282
[TBL] [Abstract][Full Text] [Related]
10. Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study.
Akuta N; Kawamura Y; Fujiyama S; Saito S; Muraishi N; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kumada H
Hepatol Commun; 2022 Sep; 6(9):2286-2297. PubMed ID: 35581956
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China.
Yu XY; Song XX; Tong YL; Wu LY; Song ZY
Medicine (Baltimore); 2020 Nov; 99(48):e23360. PubMed ID: 33235107
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology.
Akuta N; Kawamura Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Ikeda K; Kumada H
Intern Med; 2020 Aug; 59(16):1931-1937. PubMed ID: 32448832
[TBL] [Abstract][Full Text] [Related]
13. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes.
Mantovani A; Turino T; Lando MG; Gjini K; Byrne CD; Zusi C; Ravaioli F; Colecchia A; Maffeis C; Salvagno G; Lippi G; Bonora E; Targher G
Diabetes Metab; 2020 Sep; 46(4):296-303. PubMed ID: 31786361
[TBL] [Abstract][Full Text] [Related]
14. Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study.
Bañares J; Manzano-Nuñez R; Prió A; Rivera-Esteban J; Camps-Relats L; Villarejo A; Ruiz-Ortega L; Pons M; Ciudin A; Salcedo MT; Vargas V; Genescà J; Pericàs JM
Front Endocrinol (Lausanne); 2022; 13():945626. PubMed ID: 36093073
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes.
Ogawa Y; Nakahara T; Ando Y; Yamaoka K; Fujii Y; Uchikawa S; Fujino H; Ono A; Murakami E; Kawaoka T; Miki D; Yamauchi M; Tsuge M; Imamura M; Oka S
Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):989-996. PubMed ID: 37395206
[TBL] [Abstract][Full Text] [Related]
16. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
[TBL] [Abstract][Full Text] [Related]
18. Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease.
Yang X; Chang X; Wu S; Sun X; Zhu X; Wang L; Xu Y; Yao X; Rao S; Hu X; Xia M; Bian H; Yan H; Gao X
Lipids Health Dis; 2021 Mar; 20(1):27. PubMed ID: 33757528
[TBL] [Abstract][Full Text] [Related]
19. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.
Rajesh NA; Drishya L; Ambati MMR; Narayanan AL; Alex M; R KK; Abraham JJ; Vijayakumar TM
J Clin Exp Hepatol; 2022; 12(1):61-67. PubMed ID: 35068786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
